Shanghai – September 09, 2026 -- Harbour BioMed (HKEX: 02142.HK) shares became eligible for trading under the Shanghai-Hong Kong and Shenzhen-Hong Kong Stock Connect programs, opening direct access for qualified mainland Chinese investors effective immediately.

Market capitalization crosses HK$10 billion threshold

The inclusion follows the Company's market capitalization steadily surpassing HK$10 billion, placing it among large- and mid-cap biopharmaceutical issuers on the Hong Kong exchange.